 SEATTLE--BUSINESS WIRE--Omeros Corporation Nasdaq: OMER today announced that the company received a Complete Response Letter CRL from the U.S. Food and Drug Administration FDA regarding its Biologics License Application BLA for narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy HSCT-TMA. Following HSCT, patients generally have complex clinical courses and are often severely ill. HSCT-TMA increases that complexity and worsens outc 